xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

283

ICAR SINONASAL TUMORS

TABLE XXV.3 Evidence surrounding HPV DNA in NPC.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Isayeva et al. 1735

2012 1

Systematic review

154 NPC (47 HPV + )

Prevalence of HPV

Weighted prevalence of HPV DNA detection in 154 NPC patients is 31.1% (95% CI: 20.3%–44.5%) WHO type I NPC: EBV–/HPV– (56.4%), EBV–/HPV + (21.5%) WHO type II/III: EBV + /HPV– (87.5%)

Thamet al. 1736

2021

2

Systematic review

1919 NPC (1600

Prevalence of

EBV + /HPV–, 141 EBV–/HPV + , 68 EBV + /HPV + , 110 EBV–HPV–) 570 NPC (29 HPV + , 422EBV + )

EBVandHPV

Huang et al. 1651

HPV neither correlates with nor predicts survival in NPC

2022 4

Retrospective

1. LRC 2. Distant control 3. OS

case–control

Wuet al. 1652

2022 4

Retrospective case series

78 NPC (43 EBV + , 12 HPV + , 23 EBV–/HPV–)

OS

1. OS time was not significantly different between the EBV + and HPV + groupsEBV − /HPV– tumors had worst OS 2. Viral status not a significant predictor of OS There was no statistically significant difference in survival between the three groups ( p = 0.61) Viral status was not prognostic for OS OS better among patients with EBV + andHPV + compared to EBV–/HPV– No significant difference in DSS between HPV + and HPV– NPC patients HPV neither correlates with nor predicts survival in NPC 1. p16 overexpression is associated with improved PFS and LRC in patients with EBV-positive NPC 2. p16 expression may complement EBV status in predicting treatment outcomes for NPC patients

Simon et al. 1653

OS

2020 4

Retrospective

98 NPC (66 EBV + , 18 HPV + , 14 EBV/HPV–) 343 NPC (205 EBV + , 21HPV + , 12viral negative, 105 unknown) 150 NPC (93 EBV + , 21 HPV + , 36 EBV–/HPV–) 517 NPC (180 HPV + , 337HPV–) 956 NPC (308 HPV + , 648HPV–) 86 (44EBV + , 35EBV–, seven indeterminate; 40 HPV + , 26 HPV–, 20 no tissue sample; 13 EBV + /HPV + )

case–control

Verma et al. 1654

2020 4

Retrospective case series

OS

Ruuskanen et al. 1737

1. OS 2. DSS

2019 4

Retrospective case series

Wotman

2019 4

Database study [SEER]

DSS

et al. 1655

Verma et al. 1650

2018 4

Database study [NCDB] Retrospective case series

OS

Jiang et al. 1738

2016 4

1. OS 2. PFS 3. LRC

Atighechi et al. 1739

2014 4

Retrospective case series

41 NPC (9 HPV + , 32 HPV–)

1. OS 2. Recurrence

1. HPV type 16 and 18 most common subtypes 2. HPV + patients had better

prognosis and lower recurrence rates

Stenmark et al. 1740

2014 4

Retrospective case series

61NPC(26

1. OS 2. PFS 3. LRC

1. High-risk HPV infection may play an etiologic role in the development of nonendemic EBV–NPC 2. Compared with EBV + NPC,

EBV + /HPV– 18 HPV + /EBV–, 17 EBV–/HPV–)

HPV + and EBV–/HPV– NPC are associated with worse outcomes (Continues)